Lazaros Belbasis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lazaros Belbasis has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Evangelos Evangelou
Department of Epidemiology and Biostatistics, Imperial College London, London, UK
14 shared publications Vanesa Bellou
Department of Hygiene and Epidemiology, University of Ioannina Medical School, Ioannina, Greece
8 shared publications- Ioanna Tzoulaki
Imperial College London
6 shared publications - Cornelia M. van Duijn
Nuffield Department of Population Health, University of Oxford, Oxford, UK
4 shared publications - John P. A. Ioannidis
Stanford University, USA
3 shared publications Angelo Maria Pezzullo
Section of Hygiene, Department of Life Sciences and Public Health, Università Cattolica del Sacro Cuore, Rome, Italy
2 shared publications
Latest Publications
- Open Access
- 3 July 2026
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1) , 374
Integrative proteogenomic analyses identify plasma proteins that impact the risk of ischemic stroke
Background: Understanding the proteins implicated in the pathogenesis of ischemic stroke is important for elucidating disease mechanisms and informing prevention strategies. In this study, we aim to identify plasma proteins with a potentially causal effect on risk of ischemic stroke by integrating the largest available genetic data sources for plasma proteins, ischemic stroke and its risk factors. Methods: We use genome-wide association (GWA) statistics to identify cis protein quantitative trait loci for over 3,500 proteins across two proteomic platforms. Subsequently, we perform two-sample Mendelian randomization (MR) to assess the potentially causal relationships between plasma proteins and a) risk of ischemic stroke and its subtypes, and b) well-established cardiovascular risk factors. Downstream analyses include Bayesian colocalization, phenome-wide associations and interrogation of biological databases. Results: We identify 21 proteins with evidence of potentially causal associations with risk of ischemic stroke or its subtypes at 5% false discovery rate, with 16 supported further by colocalization. Four proteins (CEP85, KNG1, MMUT, SPATA20) represent findings not previously implicated in ischemic stroke through MR, or through cognate genes in GWA studies. Integration of evidence from phenome-wide MR, animal models and tissue-specific gene expression highlights agonists of MMUT, CEP85 and GRK5, and inhibitors of F11 and KNG1 as the most promising for further consideration as targets for prevention of ischemic stroke. Conclusions: Our study provides the most comprehensive data integration to date supporting the identification and causal relevance of plasma proteins for ischemic stroke and implicating a number of potential therapeutic targets.
- 3 July 2026
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1) , 374
Open AccessIntegrative proteogenomic analyses identify plasma proteins that impact the risk of ischemic stroke
Background: Understanding the proteins implicated in the pathogenesis of ischemic stroke is important for elucidating disease mechanisms and informing prevention strategies. In this study, we aim to identify plasma proteins with a potentially causal effect on risk of ischemic stroke by integrating the largest available genetic data sources for plasma proteins, ischemic stroke and its risk factors. Methods: We use genome-wide association (GWA) statistics to identify cis protein quantitative trait loci for over 3,500 proteins across two proteomic platforms. Subsequently, we perform two-sample Mendelian randomization (MR) to assess the potentially causal relationships between plasma proteins and a) risk of ischemic stroke and its subtypes, and b) well-established cardiovascular risk factors. Downstream analyses include Bayesian colocalization, phenome-wide associations and interrogation of biological databases. Results: We identify 21 proteins with evidence of potentially causal associations with risk of ischemic stroke or its subtypes at 5% false discovery rate, with 16 supported further by colocalization. Four proteins (CEP85, KNG1, MMUT, SPATA20) represent findings not previously implicated in ischemic stroke through MR, or through cognate genes in GWA studies. Integration of evidence from phenome-wide MR, animal models and tissue-specific gene expression highlights agonists of MMUT, CEP85 and GRK5, and inhibitors of F11 and KNG1 as the most promising for further consideration as targets for prevention of ischemic stroke. Conclusions: Our study provides the most comprehensive data integration to date supporting the identification and causal relevance of plasma proteins for ischemic stroke and implicating a number of potential therapeutic targets.
- Open Access
Proteomic profiling of Alzheimer’s disease and Vascular dementia reveals unique underlying signatures
INTRODUCTION: Alzheimer’s disease (AD) and vascular dementia (VaD) account for most dementia cases. AD biomarkers remain costly and invasive, and no specific biomarkers exist for VaD. METHODS: We analyzed plasma and brain proteomics in the UK Biobank (N=53,000) and ROSMAP (N=512) to identify shared and distinct proteomic signatures of AD and VaD and assess the influence of the APOE ε4 variant. RESULTS: We identified 55 AD-associated and 49 VaD-associated proteins, with 13 shared. AD proteins were enriched in glycosaminoglycan binding and cholesterol metabolism; VaD proteins in virus receptor activity, cytokine activity and metalloproteinases. Both showed IGF pathway dysregulation. APOE ε4 stratification revealed distinct AD proteomic signatures beyond GFAP and NeFL. Mendelian randomization suggested causal links for SNAP25 in AD, EDA2R and TIMP4 in VaD, and PVR in both. DISCUSSION: Findings underscore the importance of APOE genotype and highlight SNAP25, EDA2R, TIMP4, and PVR as potential biomarkers and therapeutic targets.
Open AccessProteomic profiling of Alzheimer’s disease and Vascular dementia reveals unique underlying signatures
INTRODUCTION: Alzheimer’s disease (AD) and vascular dementia (VaD) account for most dementia cases. AD biomarkers remain costly and invasive, and no specific biomarkers exist for VaD. METHODS: We analyzed plasma and brain proteomics in the UK Biobank (N=53,000) and ROSMAP (N=512) to identify shared and distinct proteomic signatures of AD and VaD and assess the influence of the APOE ε4 variant. RESULTS: We identified 55 AD-associated and 49 VaD-associated proteins, with 13 shared. AD proteins were enriched in glycosaminoglycan binding and cholesterol metabolism; VaD proteins in virus receptor activity, cytokine activity and metalloproteinases. Both showed IGF pathway dysregulation. APOE ε4 stratification revealed distinct AD proteomic signatures beyond GFAP and NeFL. Mendelian randomization suggested causal links for SNAP25 in AD, EDA2R and TIMP4 in VaD, and PVR in both. DISCUSSION: Findings underscore the importance of APOE genotype and highlight SNAP25, EDA2R, TIMP4, and PVR as potential biomarkers and therapeutic targets.
- Open Access
- 4 August 2025
- Published by Springer Nature in Research Square
Integrative proteogenomic analyses discover novel plasma proteins that impact risk of ischemic stroke
Understanding the proteins implicated in the pathogenesis of ischemic stroke is essential for developing novel prevention strategies. In this study, we compiled the largest available data sources for proteins and stroke to conduct Mendelian randomization (MR) using cis protein quantitative trait loci of over 3,500 proteins across two proteomic platforms and assess their causal relationship with ischemic stroke and its risk factors. We identified 21 potentially causal associations between proteins and ischemic stroke or its subtypes at 5% false discovery rate, with 16 supported by co-localisation. Four proteins (CEP85, KNG1, MMUT, SPATA20) represented novel findings not previously implicated in ischemic stroke through MR or genome-wide association studies. Integration of evidence from phenome-wide MR, animal models and tissue-specific gene expression highlighted agonists of MMUT, CEP85 and GRK5, and inhibitors of F11 and KNG1 as the most promising targets for prevention of ischemic stroke. Our study provides the most comprehensive data integration to date supporting the identification and causal relevance of plasma proteins for ischemic stroke.
- 4 August 2025
- Published by Springer Nature in Research Square
Open AccessIntegrative proteogenomic analyses discover novel plasma proteins that impact risk of ischemic stroke
Understanding the proteins implicated in the pathogenesis of ischemic stroke is essential for developing novel prevention strategies. In this study, we compiled the largest available data sources for proteins and stroke to conduct Mendelian randomization (MR) using cis protein quantitative trait loci of over 3,500 proteins across two proteomic platforms and assess their causal relationship with ischemic stroke and its risk factors. We identified 21 potentially causal associations between proteins and ischemic stroke or its subtypes at 5% false discovery rate, with 16 supported by co-localisation. Four proteins (CEP85, KNG1, MMUT, SPATA20) represented novel findings not previously implicated in ischemic stroke through MR or genome-wide association studies. Integration of evidence from phenome-wide MR, animal models and tissue-specific gene expression highlighted agonists of MMUT, CEP85 and GRK5, and inhibitors of F11 and KNG1 as the most promising targets for prevention of ischemic stroke. Our study provides the most comprehensive data integration to date supporting the identification and causal relevance of plasma proteins for ischemic stroke.
- Open Access
- 3 March 2025
- Published by Oxford University Press (OUP) in Brain
- Vol. 148 (7) , 2412-2428
Mendelian randomization identifies proteins involved in neurodegenerative diseases
Proteins are involved in multiple biological functions. High-throughput technologies have allowed the measurement of thousands of proteins in population biobanks. In this study, we aimed to identify proteins related to Alzheimer’s disease, Parkinson’s disease, multiple sclerosis and amyotrophic lateral sclerosis by leveraging large-scale genetic and proteomic data. We performed a two-sample cis Mendelian randomization study by selecting instrumental variables for the abundance of >2700 proteins measured by either Olink or SomaScan platforms in plasma from the UK Biobank and the deCODE Health Study. We also used the latest publicly available genome-wide association studies for the neurodegenerative diseases of interest. The potentially causal effect of proteins on neurodegenerative diseases was estimated based on the Wald ratio. We tested 13 377 protein–disease associations, identifying 169 associations that were statistically significant (5% false discovery rate). Evidence of co-localization between plasma protein abundance and disease risk (posterior probability > 0.80) was identified for 61 protein–disease pairs, leading to 50 unique protein–disease associations. Notably, 23 of 50 protein–disease associations corresponded to genetic loci not previously reported by genome-wide association studies. The two-sample Mendelian randomization and co-localization analysis also showed that APOE abundance in plasma was associated with three subcortical volumes (hippocampus, amygdala and nucleus accumbens) and white matter hyper-intensities, whereas PILRA and PILRB abundance in plasma was associated with caudate nucleus volume. Our study provided a comprehensive assessment of the effect of the human proteome that is currently measurable through two different platforms on neurodegenerative diseases. The newly associated proteins indicated the involvement of complement (C1S and C1R), microglia (SIRPA, SIGLEC9 and PRSS8) and lysosomes (CLN5) in Alzheimer’s disease; the interleukin-6 pathway (CTF1) in Parkinson’s disease; lysosomes (TPP1), blood–brain barrier integrity (MFAP2) and astrocytes (TNFSF13) in amyotrophic lateral sclerosis; and blood–brain barrier integrity (VEGFB), oligodendrocytes (PARP1), node of Ranvier and dorsal root ganglion (NCS1, FLRT3 and CDH15) and the innate immune system (CR1, AHSG and WARS) in multiple sclerosis. Our study demonstrates how harnessing large-scale genomic and proteomic data can yield new insights into the role of the plasma proteome in the pathogenesis of neurodegenerative diseases.
- 3 March 2025
- Published by Oxford University Press (OUP) in Brain
- Vol. 148 (7) , 2412-2428
Open AccessMendelian randomization identifies proteins involved in neurodegenerative diseases
Proteins are involved in multiple biological functions. High-throughput technologies have allowed the measurement of thousands of proteins in population biobanks. In this study, we aimed to identify proteins related to Alzheimer’s disease, Parkinson’s disease, multiple sclerosis and amyotrophic lateral sclerosis by leveraging large-scale genetic and proteomic data. We performed a two-sample cis Mendelian randomization study by selecting instrumental variables for the abundance of >2700 proteins measured by either Olink or SomaScan platforms in plasma from the UK Biobank and the deCODE Health Study. We also used the latest publicly available genome-wide association studies for the neurodegenerative diseases of interest. The potentially causal effect of proteins on neurodegenerative diseases was estimated based on the Wald ratio. We tested 13 377 protein–disease associations, identifying 169 associations that were statistically significant (5% false discovery rate). Evidence of co-localization between plasma protein abundance and disease risk (posterior probability > 0.80) was identified for 61 protein–disease pairs, leading to 50 unique protein–disease associations. Notably, 23 of 50 protein–disease associations corresponded to genetic loci not previously reported by genome-wide association studies. The two-sample Mendelian randomization and co-localization analysis also showed that APOE abundance in plasma was associated with three subcortical volumes (hippocampus, amygdala and nucleus accumbens) and white matter hyper-intensities, whereas PILRA and PILRB abundance in plasma was associated with caudate nucleus volume. Our study provided a comprehensive assessment of the effect of the human proteome that is currently measurable through two different platforms on neurodegenerative diseases. The newly associated proteins indicated the involvement of complement (C1S and C1R), microglia (SIRPA, SIGLEC9 and PRSS8) and lysosomes (CLN5) in Alzheimer’s disease; the interleukin-6 pathway (CTF1) in Parkinson’s disease; lysosomes (TPP1), blood–brain barrier integrity (MFAP2) and astrocytes (TNFSF13) in amyotrophic lateral sclerosis; and blood–brain barrier integrity (VEGFB), oligodendrocytes (PARP1), node of Ranvier and dorsal root ganglion (NCS1, FLRT3 and CDH15) and the innate immune system (CR1, AHSG and WARS) in multiple sclerosis. Our study demonstrates how harnessing large-scale genomic and proteomic data can yield new insights into the role of the plasma proteome in the pathogenesis of neurodegenerative diseases.
- Open Access
A Mendelian randomization study identifies proteins involved in neurodegenerative diseases
Proteins are involved in multiple biological functions. High-throughput technologies have allowed the measurement of thousands of proteins in population biobanks. In this study, we aimed to identify proteins related to Alzheimer’s disease (AD), Parkinson’s disease (PD), Multiple Sclerosis (MS) and Amyotrophic Lateral Sclerosis (ALS) using large-scale genetic and proteomic data. We performed a two-sample cis Mendelian randomization (MR) study by selecting instrumental variables for the abundance of over 2,700 proteins measured by either Olink or SomaScan platforms in plasma from UK Biobank and the deCODE Health Study. We also used the latest publicly-available GWAS for the diseases of interest. The potentially causal effect of proteins on neurodegenerative diseases was estimated based on the Wald ratio. We tested 10,244 protein–disease associations, identifying 122 associations which were statistically significant (5% false discovery rate). Out of 57 associations (58%) tested using an instrumental variable from both Olink and SomaScan platforms, 33 (58%) were statistically significant in both platforms. Evidence of co-localisation between plasma protein abundance and disease risk (posterior probability >0.80) was identified for 46 protein-disease pairs. Twenty-three out of 46 protein–disease associations correspond to genetic loci not previously reported by genome-wide association studies. The newly-associated proteins for AD are involved in complement (C1S, C1R), microglia (SIRPA, PRSS8) and lysosomal functions (CLN5). A protein newly-associated with PD (CTF1) is involved in the interleukin-6 pathway, two proteins for ALS (TPP1, TNFSF13) are involved in lysosomal and astrocyte function, respectively, and proteins associated with MS are involved in blood–brain barrier function (TYMP, VEGFB), the oligodendrocyte function (PARP1), the structure of the node of Ranvier and function of dorsal root ganglion (NCS1, FLRT3, CDH15), and the response to viral infections including Epstein-Barr virus (PVR, WARS1). Our study demonstrates how harnessing large-scale genomic and proteomic data can yield novel insights into the role of plasma proteome in the pathogenesis of neurodegenerative diseases.
Open AccessA Mendelian randomization study identifies proteins involved in neurodegenerative diseases
Proteins are involved in multiple biological functions. High-throughput technologies have allowed the measurement of thousands of proteins in population biobanks. In this study, we aimed to identify proteins related to Alzheimer’s disease (AD), Parkinson’s disease (PD), Multiple Sclerosis (MS) and Amyotrophic Lateral Sclerosis (ALS) using large-scale genetic and proteomic data. We performed a two-sample cis Mendelian randomization (MR) study by selecting instrumental variables for the abundance of over 2,700 proteins measured by either Olink or SomaScan platforms in plasma from UK Biobank and the deCODE Health Study. We also used the latest publicly-available GWAS for the diseases of interest. The potentially causal effect of proteins on neurodegenerative diseases was estimated based on the Wald ratio. We tested 10,244 protein–disease associations, identifying 122 associations which were statistically significant (5% false discovery rate). Out of 57 associations (58%) tested using an instrumental variable from both Olink and SomaScan platforms, 33 (58%) were statistically significant in both platforms. Evidence of co-localisation between plasma protein abundance and disease risk (posterior probability >0.80) was identified for 46 protein-disease pairs. Twenty-three out of 46 protein–disease associations correspond to genetic loci not previously reported by genome-wide association studies. The newly-associated proteins for AD are involved in complement (C1S, C1R), microglia (SIRPA, PRSS8) and lysosomal functions (CLN5). A protein newly-associated with PD (CTF1) is involved in the interleukin-6 pathway, two proteins for ALS (TPP1, TNFSF13) are involved in lysosomal and astrocyte function, respectively, and proteins associated with MS are involved in blood–brain barrier function (TYMP, VEGFB), the oligodendrocyte function (PARP1), the structure of the node of Ranvier and function of dorsal root ganglion (NCS1, FLRT3, CDH15), and the response to viral infections including Epstein-Barr virus (PVR, WARS1). Our study demonstrates how harnessing large-scale genomic and proteomic data can yield novel insights into the role of plasma proteome in the pathogenesis of neurodegenerative diseases.
- Open Access
- 14 July 2023
- Published by Springer Nature in Systematic Reviews
- Vol. 12 (1) , 1-6
Mapping and systematic appraisal of umbrella reviews in epidemiological research: a protocol for a meta-epidemiological study
Introduction: Umbrella review is one of the terms used to describe an overview of systematic reviews. During the last years, a rapid increase in the number of umbrella reviews on epidemiological studies has been observed, but there is no systematic assessment of their methodological and reporting characteristics. Our study aims to fill this gap by performing a systematic mapping of umbrella reviews in epidemiological research. Methods: We will perform a meta-epidemiological study including a systematic review in MEDLINE and EMBASE to identify all the umbrella reviews that focused on systematic reviews of epidemiological studies and were published from inception until December 31, 2022. We will consider eligible any research article which was designed as an umbrella review and summarized systematic reviews and meta-analyses of epidemiological studies. From each eligible article, we will extract information about the research topic, the methodological characteristics, and the reporting characteristics. We will examine whether the umbrella reviews assessed the strength of the available evidence and the rigor of the included systematic reviews. We will also examine whether these characteristics change across time. Discussion: Our study will systematically appraise the methodological and reporting characteristics of published umbrella reviews in epidemiological literature. The findings of our study can be used to improve the design and conduct of future umbrella reviews, to derive a standardized set of reporting and methodological guidelines for umbrella reviews, and to allow further meta-epidemiological work. Systematic review registration: osf.io/sxzc6
- 14 July 2023
- Published by Springer Nature in Systematic Reviews
- Vol. 12 (1) , 1-6
Open AccessMapping and systematic appraisal of umbrella reviews in epidemiological research: a protocol for a meta-epidemiological study
Introduction: Umbrella review is one of the terms used to describe an overview of systematic reviews. During the last years, a rapid increase in the number of umbrella reviews on epidemiological studies has been observed, but there is no systematic assessment of their methodological and reporting characteristics. Our study aims to fill this gap by performing a systematic mapping of umbrella reviews in epidemiological research. Methods: We will perform a meta-epidemiological study including a systematic review in MEDLINE and EMBASE to identify all the umbrella reviews that focused on systematic reviews of epidemiological studies and were published from inception until December 31, 2022. We will consider eligible any research article which was designed as an umbrella review and summarized systematic reviews and meta-analyses of epidemiological studies. From each eligible article, we will extract information about the research topic, the methodological characteristics, and the reporting characteristics. We will examine whether the umbrella reviews assessed the strength of the available evidence and the rigor of the included systematic reviews. We will also examine whether these characteristics change across time. Discussion: Our study will systematically appraise the methodological and reporting characteristics of published umbrella reviews in epidemiological literature. The findings of our study can be used to improve the design and conduct of future umbrella reviews, to derive a standardized set of reporting and methodological guidelines for umbrella reviews, and to allow further meta-epidemiological work. Systematic review registration: osf.io/sxzc6
- Top Cited PapersOpen Access
- 22 November 2022
- Published by BMJ in BMJ Medicine
- Vol. 1 (1) , e000071
Conducting umbrella reviews
In this article, Lazaros Belbasis and colleagues explain the rationale for umbrella reviews and the key steps involved in conducting an umbrella review, using a working example.
- 22 November 2022
- Published by BMJ in BMJ Medicine
- Vol. 1 (1) , e000071
Top Cited PapersOpen AccessConducting umbrella reviews
In this article, Lazaros Belbasis and colleagues explain the rationale for umbrella reviews and the key steps involved in conducting an umbrella review, using a working example.
- Open Access
- 25 October 2022
- Published by Oxford University Press (OUP) in European Journal of Public Health
- Vol. 32 (Supplement)
Quality of COVID-19 research: An overview of large-scale assessments and a case study on excess mortality estimates
COVID-19 is an ongoing public health emergency, which affected individual and population health, whereas it disrupted social and economic activities for more than 2 years. High-quality research evidence, which is published without delays in the peer-review and publication pipeline, is the most powerful tool for evidence-based decision-making by physicians, public health and health policy specialists, and politicians. However, from the early stages of the pandemic till now, there is a debate on the quality of COVID-19 research, whereas it has been observed that the decrease in the time from submission to publication was accompanied by a decrease in research quality. This presentation discusses the findings and main conclusions from two research projects. The first part focuses on a systematic review of published large-scale qualitative evaluations of COVID-19 research. By taking advantage of these large-scale assessments, we will provide a bird's eye view on the quality of COVID-19 research done so far. The second part focuses on a case study describing the methodological quality of studies calculating excess mortality estimates during COVID-19 pandemic. Excess mortality estimates depend on important choices about the pre-pandemic reference period, the pandemic period of interest, and the modelling of the comparison between these two periods. Such an assessment has not been done yet although there is an abundance of published approaches to estimate excess mortality during the COVID-19 pandemic. Overall, these two projects highlight the importance of meta-research in the time of pandemic by scrutinizing and assessing scientific evidence while deriving recommendations for improvement of future research. This presentation concludes with a summary of the implications of low-quality COVID-19 research in decision-making and some general considerations to improve research quality and integrity in the case of future pandemics.
- 25 October 2022
- Published by Oxford University Press (OUP) in European Journal of Public Health
- Vol. 32 (Supplement)
Open AccessQuality of COVID-19 research: An overview of large-scale assessments and a case study on excess mortality estimates
COVID-19 is an ongoing public health emergency, which affected individual and population health, whereas it disrupted social and economic activities for more than 2 years. High-quality research evidence, which is published without delays in the peer-review and publication pipeline, is the most powerful tool for evidence-based decision-making by physicians, public health and health policy specialists, and politicians. However, from the early stages of the pandemic till now, there is a debate on the quality of COVID-19 research, whereas it has been observed that the decrease in the time from submission to publication was accompanied by a decrease in research quality. This presentation discusses the findings and main conclusions from two research projects. The first part focuses on a systematic review of published large-scale qualitative evaluations of COVID-19 research. By taking advantage of these large-scale assessments, we will provide a bird's eye view on the quality of COVID-19 research done so far. The second part focuses on a case study describing the methodological quality of studies calculating excess mortality estimates during COVID-19 pandemic. Excess mortality estimates depend on important choices about the pre-pandemic reference period, the pandemic period of interest, and the modelling of the comparison between these two periods. Such an assessment has not been done yet although there is an abundance of published approaches to estimate excess mortality during the COVID-19 pandemic. Overall, these two projects highlight the importance of meta-research in the time of pandemic by scrutinizing and assessing scientific evidence while deriving recommendations for improvement of future research. This presentation concludes with a summary of the implications of low-quality COVID-19 research in decision-making and some general considerations to improve research quality and integrity in the case of future pandemics.
- Open Access
- 29 July 2022
- Published by Springer Nature in Research Square
Mapping and systematic appraisal of umbrella reviews in biomedical literature: A protocol
Introduction: Umbrella reviews have emerged as a study design to deal with the increasing number of systematic reviews and meta-analyses. There is a rapid increase in the number of umbrella reviews being published, but there is no systematic assessment of their methodological and reporting characteristics. Our study will aim to fill this gap by performing a systematic mapping of umbrella reviews in biomedical literature. Methods We will perform a systematic review in PubMed to identify all the umbrella reviews that were published from inception until March 11, 2022. We will consider eligible any research article which was designated as an umbrella review in its title or abstract and summarizes systematic reviews and meta-analyses of any type of studies. From each eligible article, we will extract information about the research topic, the methodological characteristics, and the reporting characteristics. We will examine whether the umbrella reviews assessed the strength of the available evidence and the rigor of the included systematic reviews. We will also examine whether these characteristics change across time. Discussion Our study will systematically appraise the methodological and reporting characteristics of published umbrella reviews in biomedical literature. The findings of our study can be used to improve the design and conduct of future umbrella reviews, to derive a standardized set of reporting and methodological guidelines for umbrella reviews, and to allow further meta-epidemiological work. Systematic review registration: osf.io/sxzc6
- 29 July 2022
- Published by Springer Nature in Research Square
Open AccessMapping and systematic appraisal of umbrella reviews in biomedical literature: A protocol
Introduction: Umbrella reviews have emerged as a study design to deal with the increasing number of systematic reviews and meta-analyses. There is a rapid increase in the number of umbrella reviews being published, but there is no systematic assessment of their methodological and reporting characteristics. Our study will aim to fill this gap by performing a systematic mapping of umbrella reviews in biomedical literature. Methods We will perform a systematic review in PubMed to identify all the umbrella reviews that were published from inception until March 11, 2022. We will consider eligible any research article which was designated as an umbrella review in its title or abstract and summarizes systematic reviews and meta-analyses of any type of studies. From each eligible article, we will extract information about the research topic, the methodological characteristics, and the reporting characteristics. We will examine whether the umbrella reviews assessed the strength of the available evidence and the rigor of the included systematic reviews. We will also examine whether these characteristics change across time. Discussion Our study will systematically appraise the methodological and reporting characteristics of published umbrella reviews in biomedical literature. The findings of our study can be used to improve the design and conduct of future umbrella reviews, to derive a standardized set of reporting and methodological guidelines for umbrella reviews, and to allow further meta-epidemiological work. Systematic review registration: osf.io/sxzc6
- Open Access
- 11 June 2022
- Published by Springer Nature in BMC Research Notes
- Vol. 15 (1) , 1-5
Reproducibility of prediction models in health services research
The field of health services research studies the health care system by examining outcomes relevant to patients and clinicians but also health economists and policy makers. Such outcomes often include health care spending, and utilization of care services. Building accurate prediction models using reproducible research practices for health services research is important for evidence-based decision making. Several systematic reviews have summarized prediction models for outcomes relevant to health services research, but these systematic reviews do not present a thorough assessment of reproducibility and research quality of the prediction modelling studies. In the present commentary, we discuss how recent advances in prediction modelling in other medical fields can be applied to health services research. We also describe the current status of prediction modelling in health services research, and we summarize available methodological guidance for the development, update, external validation and systematic appraisal of prediction models.
- 11 June 2022
- Published by Springer Nature in BMC Research Notes
- Vol. 15 (1) , 1-5
Open AccessReproducibility of prediction models in health services research
The field of health services research studies the health care system by examining outcomes relevant to patients and clinicians but also health economists and policy makers. Such outcomes often include health care spending, and utilization of care services. Building accurate prediction models using reproducible research practices for health services research is important for evidence-based decision making. Several systematic reviews have summarized prediction models for outcomes relevant to health services research, but these systematic reviews do not present a thorough assessment of reproducibility and research quality of the prediction modelling studies. In the present commentary, we discuss how recent advances in prediction modelling in other medical fields can be applied to health services research. We also describe the current status of prediction modelling in health services research, and we summarize available methodological guidance for the development, update, external validation and systematic appraisal of prediction models.